| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2020 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 12,000 | $21.97 | $263,640.00 | +42.9% | |
| Mar 13, 2020 | PRGO Perrigo Co Plc | Samuels Theodore R. II51 | Director | Buy | 2,000 | $42.50 | $85,000.00 | +17.2% | |
| Mar 13, 2020 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 4,701 | $13.94 | $65,538.67 | -3.0% | |
| Mar 12, 2020 | BHC Bausch Health Companies Inc. | Ross Thomas W. Sr. | Director | Buy | 2,500 | $15.54 | $38,837.50 | +3.3% | |
| Mar 11, 2020 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 2,500 | $43.00 | $107,500.00 | +2.3% | |
| Mar 11, 2020 | PCRX Pacira Biosciences, Inc. | Winston Roy68 | Chief Clinical Officer | Buy | 2,500 | $36.50 | $91,250.00 | +11.0% | |
| Mar 10, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Patel Chirag K. | President, Co-ceo &Director | Buy | 100,000 | $3.09 | $309,000.00 | +39.0% | |
| Mar 10, 2020 | BHC Bausch Health Companies Inc. | Von Eschenbach Andrew C. | Director | Buy | 1,100 | $18.18 | $19,996.35 | +6.3% | |
| Mar 10, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Patel Chintu | Co-ceo And Director | Buy | 100,000 | $3.09 | $309,000.00 | +39.0% | |
| Mar 10, 2020 | AYTU Aytu Biopharma, Inc | Armistice Capital, LLC56 | Director | Sell | 22,026,801 | $1.42 | $31,200,122.91 | -81.8% | |
| Mar 10, 2020 | BHC Bausch Health Companies Inc. | Ackermann Christina | EVP And General Counsel | Buy | 4,390 | $18.25 | $80,105.65 | +5.0% | |
| Mar 10, 2020 | BHC Bausch Health Companies Inc. | De Schutter Richard U | Director | Buy | 8,800 | $21.00 | $184,792.36 | +3.1% | |
| Mar 9, 2020 | YCBD Cbdmd, Inc. | Ghiloni Peter J. | Director | Buy | 25,000 | $0.75 | $18,720.00 | +9.1% | |
| Mar 9, 2020 | ELAN Elanco Animal Health Inc | Harrington Michael J | Director | Buy | 4,000 | $23.84 | $95,360.00 | +31.3% | |
| Mar 9, 2020 | SNY Sanofi | Sanofi | 10% Owner | Sell | 128,914 | $489.65 | $63,123,152.62 | -0.6% | |
| Mar 6, 2020 | KNSA Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | Chairman &CEO | Sell | 33,115 | $20.00 | $662,300.00 | -13.5% | |
| Mar 6, 2020 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | SVP And General Counsel | Sell | 1,936 | $14.58 | $28,228.82 | -1.4% | |
| Mar 6, 2020 | ELAN Elanco Animal Health Inc | Bilbrey John P49 | Director | Buy | 3,000 | $25.15 | $75,450.00 | +25.8% | |
| Mar 5, 2020 | ZTS Zoetis Inc. | David Glenn | Chief Financial Officer | Sell | 43,778 | $140.89 | $6,167,794.38 | -42.4% | |
| Mar 5, 2020 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 9,019 | $15.35 | $138,408.28 | -1.3% | |
| Mar 4, 2020 | LLY Eli Lilly & Co | O'Neill Myles | SVP &Pres., Mfg. Operations | Sell | 25,000 | $140.15 | $3,503,750.00 | -74.7% | |
| Mar 4, 2020 | BMY Bristol Myers Squibb Co | Elicker John E | EVP, Investor Relations | Sell | 15,805 | $61.01 | $964,263.05 | -21.2% | |
| Mar 4, 2020 | EBS Emergent Biosolutions Inc. | Sullivan Louis W62 | Director | Sell | 15,786 | $58.96 | $930,714.15 | -11.5% | |
| Mar 4, 2020 | ELAN Elanco Animal Health Inc | Anand Kapila K | Director | Buy | 1,000 | $26.86 | $26,860.00 | +8.1% | |
| Mar 4, 2020 | AMRN Amarin Corp Plc\uk | Thero John F | President And CEO | Sell | 200,000 | $15.99 | $3,198,700.00 | -7.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.